BindingDB

null

SMILES CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC

InChI Key InChIKey=WAOQONBSWFLFPE-VIFPVBQESA-N

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 50005118

D(2) dopamine receptor(Rattus norvegicus (rat))
University of Lund

Curated by ChEMBL

BDBM50005118((S)-3,5-Dichloro-N-(1-ethyl-pyrrolidin-2-ylmethyl)...)copy SMILEScopy InChI

Ki: 9.5nMAssay Description:Compound was evaluated for binding affinity towards DA D-2 receptor using radioligand [3H]SPIMore data for this Ligand-Target Pair

PDB Reactome pathway KEGG
UniProtKB/SwissProt
GoogleScholar

Purchase CHEMBL MCE
PC cid PC sid Patents Similars

Details
BindingDB Entry DOI: 10.7270/Q2R2120BPubMed

D(2) dopamine receptor(Rattus norvegicus (rat))
University of Lund

Curated by ChEMBL

BDBM50005118((S)-3,5-Dichloro-N-(1-ethyl-pyrrolidin-2-ylmethyl)...)copy SMILEScopy InChI

IC50: 32nMAssay Description:Compound was evaluated for binding affinity towards DA D-2 receptor using radioligand [3H]SPIMore data for this Ligand-Target Pair

PDB Reactome pathway KEGG
UniProtKB/SwissProt
GoogleScholar

Purchase CHEMBL MCE
PC cid PC sid Patents Similars

Details
BindingDB Entry DOI: 10.7270/Q2R2120BPubMed

Targets 15 ▿
- D(2) dopamine receptor 44
- D(3) dopamine receptor 9
- D(4) dopamine receptor 8
- D(1A) dopamine receptor 5
- 5-hydroxytryptamine receptor 2A 4
- D(1A)/D(1B)/D(2)/D(3)/D(4) dopamine receptor 3
- Alpha-2C adrenergic receptor 1
- Alpha-1A adrenergic receptor 1
- Histamine H1 receptor 1
- 5-hydroxytryptamine receptor 2C 1
- 5-hydroxytryptamine receptor 1A 1
- Muscarinic acetylcholine receptor M2 1
- 5-hydroxytryptamine receptor 7 1
- 5-hydroxytryptamine receptor 6 1
- Beta-2 adrenergic receptor 1
- ...
Publications 35 ▿
- Acta Pharmacol Toxicol (Copenh) 58: 61-70 (1986) 12
- J Pharmacol Exp Ther 268: 1403-10 (1994) 5
- Nature 350: 610-4 (1991) 4
- ACS Med Chem Lett 11: 385-392 (2020) 4
- Mol Psychiatry 3: 123-34 (1998) 4
- Bioorg Med Chem 15: 6819-29 (2007) 4
- Pharmacol Rev 53: 119-33 (2001) 3
- J Med Chem 33: 2430-7 (1990) 3
- Neuropsychopharmacology 16: 93 (1997) 3
- J Med Chem 35: 2355-63 (1992) 2
- Eur J Pharmacol 146: 113-20 (1988) 2
- J Med Chem 59: 7634-50 (2016) 2
- J Med Chem 34: 1612-24 (1991) 2
- Mol Pharmacol 43: 749-54 (1993) 2
- J Med Chem 31: 2027-33 (1988) 2
- Eur J Pharmacol 236: 483-6 (1993) 2
- J Med Chem 57: 4962-8 (2014) 2
- J Med Chem 31: 1039-43 (1988) 2
- J Med Chem 34: 948-55 (1991) 2
- J Med Chem 33: 1155-63 (1990) 2
- Nature 347: 146-51 (1990) 2
- J Pharmacol Exp Ther 282: 1011-9 (1997) 2
- Bioorg Med Chem Lett 13: 4015-7 (2003) 2
- Synapse 25: 137-46 (1997) 1
- J Med Chem 46: 4377-92 (2003) 1
- J Med Chem 36: 1499-500 (1993) 1
- J Med Chem 29: 61-9 (1986) 1
- Eur J Med Chem 101: 367-83 (2015) 1
- Bioorg Med Chem 24: 4759-4765 (2016) 1
- J Med Chem 45: 4655-68 (2002) 1
- J Med Chem 57: 4368-81 (2014) 1
- J Med Chem 33: 171-8 (1990) 1
- J Med Chem 33: 2305-9 (1990) 1
- J Med Chem 36: 221-8 (1993) 1
- J Pharmacol Exp Ther 282: 181-91 (1997) 1
Institutions 26 ▿
- [Astra Läkemedel AB, University of Toronto] 12
- [Astra Läkemedel AB, University of Toronto] 12
- [University of Pennsylvania, Astra Research Centre AB, Case Western Reserve University] 5
- [University of Pennsylvania, Astra Research Centre AB, Case Western Reserve University] 5
- [University of Pennsylvania, Astra Research Centre AB, Case Western Reserve University] 5
- [Duke University, Johannes Gutenberg-University] 4
- [Duke University, Johannes Gutenberg-University] 4
- [University of Michigan, University of Reading, Washington University School of Medicine] 3
- [University of Michigan, University of Reading, Washington University School of Medicine] 3
- [University of Michigan, University of Reading, Washington University School of Medicine] 3
- [U. 109, University of Lund, Yale University, NOVO Industri A/S, Maryland Psychiatric Research Center, Neurogen Corporation, National Institute on Drug Abuse-Intramural Research Program, University of California, Astra Arcus AB, Vanderbilt University] 2
- [U. 109, University of Lund, Yale University, NOVO Industri A/S, Maryland Psychiatric Research Center, Neurogen Corporation, National Institute on Drug Abuse-Intramural Research Program, University of California, Astra Arcus AB, Vanderbilt University] 2
- [U. 109, University of Lund, Yale University, NOVO Industri A/S, Maryland Psychiatric Research Center, Neurogen Corporation, National Institute on Drug Abuse-Intramural Research Program, University of California, Astra Arcus AB, Vanderbilt University] 2
- [U. 109, University of Lund, Yale University, NOVO Industri A/S, Maryland Psychiatric Research Center, Neurogen Corporation, National Institute on Drug Abuse-Intramural Research Program, University of California, Astra Arcus AB, Vanderbilt University] 2
- [U. 109, University of Lund, Yale University, NOVO Industri A/S, Maryland Psychiatric Research Center, Neurogen Corporation, National Institute on Drug Abuse-Intramural Research Program, University of California, Astra Arcus AB, Vanderbilt University] 2
- [U. 109, University of Lund, Yale University, NOVO Industri A/S, Maryland Psychiatric Research Center, Neurogen Corporation, National Institute on Drug Abuse-Intramural Research Program, University of California, Astra Arcus AB, Vanderbilt University] 2
- [U. 109, University of Lund, Yale University, NOVO Industri A/S, Maryland Psychiatric Research Center, Neurogen Corporation, National Institute on Drug Abuse-Intramural Research Program, University of California, Astra Arcus AB, Vanderbilt University] 2
- [U. 109, University of Lund, Yale University, NOVO Industri A/S, Maryland Psychiatric Research Center, Neurogen Corporation, National Institute on Drug Abuse-Intramural Research Program, University of California, Astra Arcus AB, Vanderbilt University] 2
- [U. 109, University of Lund, Yale University, NOVO Industri A/S, Maryland Psychiatric Research Center, Neurogen Corporation, National Institute on Drug Abuse-Intramural Research Program, University of California, Astra Arcus AB, Vanderbilt University] 2
- [U. 109, University of Lund, Yale University, NOVO Industri A/S, Maryland Psychiatric Research Center, Neurogen Corporation, National Institute on Drug Abuse-Intramural Research Program, University of California, Astra Arcus AB, Vanderbilt University] 2
- [TBA, Institut de Recherches Servier, University of British Columbia, Universit£ degli Studi di Milano, McGill University, Universit£ degli Studi di Sassari] 1
- [TBA, Institut de Recherches Servier, University of British Columbia, Universit£ degli Studi di Milano, McGill University, Universit£ degli Studi di Sassari] 1
- [TBA, Institut de Recherches Servier, University of British Columbia, Universit£ degli Studi di Milano, McGill University, Universit£ degli Studi di Sassari] 1
- [TBA, Institut de Recherches Servier, University of British Columbia, Universit£ degli Studi di Milano, McGill University, Universit£ degli Studi di Sassari] 1
- [TBA, Institut de Recherches Servier, University of British Columbia, Universit£ degli Studi di Milano, McGill University, Universit£ degli Studi di Sassari] 1
- [TBA, Institut de Recherches Servier, University of British Columbia, Universit£ degli Studi di Milano, McGill University, Universit£ degli Studi di Sassari] 1
Affinity: 0.60 to 3.7E+4 nM▿
- Ki 65
- IC50 14
- Kd 3
- Affinity ≤ nM
Xtal structures: 0
Docked structures: 0
Catalog Cmpds: 1